Original Article
Breast Cancer and Other Second Neoplasms after Childhood Hodgkin's Disease
N Engl J Med 1996; 334:745-751March 21, 1996
- Abstract
Background
Patients who survive Hodgkin's disease are at increased risk for second neoplasms. As survival times increase, solid tumors are emerging as a serious long-term complication.
Methods
The Late Effects Study Group followed a cohort of 1380 children with Hodgkin's disease to determine the incidence of second neoplasms and the risk factors associated with them.
Results
In this cohort, there were 88 second neoplasms as compared with 4.4 expected in the general population (standardized incidence ratio, 18.1; 95 percent confidence interval, 14.3 to 22.3). The estimated actuarial incidence of any second neoplasm 15 years after the diagnosis of Hodgkin's disease was 7.0 percent (95 percent confidence interval, 5.2 to 8.8 percent); the incidence of solid tumors was 3.9 percent (95 percent confidence interval, 2.3 to 5.5 percent). Breast cancer was the most common solid tumor (standardized incidence ratio, 75.3; 95 percent confidence interval, 44.9 to 118.4), with an estimated actuarial incidence in women that approached 35 percent (95 percent confidence interval, 17.4 to 52.6 percent) by 40 years of age. Older age (10 to 16 vs. <10 years) at the time of radiation treatment (relative risk, 1.9) and a higher dose (2000 to 4000 vs. <2000 cGy) of radiation (relative risk, 5.9) were associated with significantly increased risk of breast cancer. The estimated actuarial incidence of leukemia reached a plateau of 2.8 percent (95 percent confidence interval, 0.8 to 4.8 percent) 14 years after diagnosis. Treatment with alkylating agents, older age at the diagnosis of Hodgkin's disease, recurrence of Hodgkin's disease, and a late stage of disease at diagnosis were risk factors for leukemia.
Conclusions
The risk of solid tumors, especially breast cancer, is high among women who were treated with radiation for childhood Hodgkin's disease. Systematic screening for breast cancer could be important in the health care of such women.
Media in This Article
Figure 2
Cumulative Probability of Breast Cancer as a Function of Age in the Cohort of Female Survivors of Hodgkin's Disease in Childhood.Figure 1
Cumulative Probability of Second Cancers in 1380 Patients with Hodgkin's Disease in Childhood.Article Activity
- Article
Long-term sequelae of the treatment of Hodgkin's disease are being encountered with increasing frequency because of the marked improvement in survival.1-4 Second neoplasms, particularly acute myelogenous leukemia, are well-known late complications in patients who have been treated for Hodgkin's disease as adults.5-15 An increased risk of second neoplasms in patients treated for Hodgkin's disease in childhood has also been reported by the Late Effects Study Group16 and others.17,18 In an earlier study, we estimated the cumulative probability of any second neoplasm to be 20 percent (4 percent for leukemia and 16 percent for solid tumors) 20 years after a diagnosis of Hodgkin's disease in childhood.16 To investigate further the incidence of second neoplasms after the treatment of childhood Hodgkin's disease and to identify specific factors associated with the risk, we extended the median follow-up for the cohort of the Late Effects Study Group from 7 to 11.4 years and increased the size of the cohort from 979 to 1380.
Methods
Fifteen institutions participated in this study (see the Appendix). The cohort consisted of children who were less than 16 years of age when their Hodgkin's disease was diagnosed and who received their primary treatment between 1955 and 1986 at a participating institution.
At each institution, a roster of all patients with Hodgkin's disease was prepared, and data were abstracted from the clinical records. Doses, fields, and equipment used in radiation therapy were noted, as were agents, doses, and durations of chemotherapy. For each patient, the date of last contact was obtained from the clinical records. For patients in whom second neoplasms developed, the date of diagnosis, the histologic characteristics and site of the tumor, and whether the tumor arose in the radiation-therapy field were recorded. If the patient died, the date and cause of death were also reported. Pathological findings were confirmed at the treating institution. The length of time at risk for second neoplasms was computed from the date of the diagnosis of Hodgkin's disease to the date of the diagnosis of the second neoplasm, the date of death, or the date of last contact, whichever came first.
For purposes of analysis, patients were classified in one of three mutually exclusive treatment groups. The first group received radiation therapy alone, the second group received chemotherapy alone, and the third group received both radiation therapy and chemotherapy (the latter either as part of the primary treatment or as salvage therapy for recurrence).
Patients who were treated with alkylating agents were analyzed separately. The following drugs were included in that class: mechlorethamine hydrochloride, cyclophosphamide, chlorambucil, procarbazine, nitrosoureas, triethylenemelamine, thiotepa, and dacarbazine. A score for the doses of alkylating agents received by each patient16 was calculated as follows: a single alkylating agent administered for at least six months was assigned a score of 1; two alkylating agents for six months, a score of 2; and so on. All such scores corresponding to the patient's treatment course were added together and rounded to the nearest integer.
To estimate the risk of second neoplasms, the number of person-years of observation was compiled for subgroups of the cohort defined by age and sex. rates of incidence of cancer (obtained from the registry of the Surveillance, Epidemiology, and End Results Program of the National Institutes of Health19) were used to calculate the expected number of cases of cancer. Standardized incidence ratios were calculated as the ratios of observed to expected cases. The 95 percent confidence intervals were estimated by a method described by Vandenbroucke.20 Cumulative probabilities of second neoplasms were calculated with actuarial methods.21 Cox regression techniques were used to calculate estimates of relative risk. Variables included in the regression model were sex, age at the diagnosis of Hodgkin's disease, clinical stage of the disease, treatment group, whether splenectomy had been performed, the alkylating-agent score, and the dose of radiation. Recurrence was included as a time-dependent covariate in the regression model. Age at the diagnosis of Hodgkin's disease was analyzed both as a categorical variable (less than 10 years or 10 to 16 years) and as a continuous variable. Clinical stages I and II and clinical stages III and IV were grouped because of the strong correlation between treatment and clinical presentation.
Results
The median duration of follow-up was 11.4 years, and 80 percent of the cohort of 1380 eligible patients with Hodgkin's disease were alive at the time of last contact (Table 1Table 1
Characteristics of the Patients.). At the time data were abstracted, there had been documented contact with approximately 71 percent of the patients within the previous five years and with 54 percent of the patients within the previous two years. Treatment for Hodgkin's disease consisted of radiation and chemotherapy in 69 percent of the patients, radiation alone in 23 percent, and chemotherapy alone in 8 percent. Among the patients who received radiation therapy, orthovoltage techniques were used for treatment in only 2 percent.Second neoplasms developed in 109 patients: 56 had solid cancers, 26 had leukemia, 6 had non-Hodgkin's lymphoma, and 21 had benign tumors. The benign tumors included 12 thyroid adenomas, 4 osteochondromas, 3 fibroadenomas of the breast, and 2 dysplastic nevi.
The numbers of observed and expected second cancers are shown in Table 2Table 2
Observed and Expected Rates of Second Cancers in the Entire Cohort, According to Type and Site.. There were significantly elevated relative risks for all cancers combined, for leukemia, for non-Hodgkin's lymphoma, and for breast, thyroid, bone, central nervous system, colorectal, and gastric cancers.Figure 1Figure 1
Cumulative Probability of Second Cancers in 1380 Patients with Hodgkin's Disease in Childhood. shows the actuarial risks of all second cancers, solid tumors, leukemia, and non-Hodgkin's lymphoma. The mean cumulative incidence of any second cancer was 7.0 percent (95 percent confidence interval, 5.2 to 8.8 percent) at 15 years. Most of this risk was due to solid tumors; the steep increase in the cumulative incidence of solid tumors began 12 years after the diagnosis of Hodgkin's disease, and the risk rose to 3.9 percent (95 percent confidence interval, 2.3 to 5.5 percent) at 15 years. In contrast, the risk of leukemia reached a plateau at 2.8 percent (95 percent confidence interval, 0.8 to 4.8 percent), and the risk of non-Hodgkin's lymphoma plateaued at 1.1 percent (95 percent confidence interval, 0 to 3.1 percent).We also estimated the standardized incidence ratio for cancer according to the period of observation (i.e., the interval from first treatment to the diagnosis of a second cancer) (Table 3Table 3
Standardized Risk Ratios for Second Cancers, According to the Length of the Follow-up Interval.). The standardized incidence ratio was highest during the first five years of follow-up and gradually declined thereafter. This phenomenon is consistent with the increase in the expected incidence of cancer with increasing age. For leukemia, the excess risk appeared within the first 5 years of treatment and declined over the next 10 years of follow-up. No cases of leukemia were observed beyond 15 years after the diagnosis of Hodgkin's disease.Leukemia
Leukemia developed in 26 patients. Twenty-four of them had acute myeloid leukemia, one had acute lymphoblastic leukemia, and one had chronic myeloid leukemia. There were no cases of leukemia in the group treated only with radiotherapy. The cumulative risks of leukemia (at 15 years) were higher in the group of patients who received chemotherapy alone (7.9 percent; 95 percent confidence interval, 1.0 to 14.8 percent) than among the patients who were treated with both radiation and chemotherapy (3.4 percent; 95 percent confidence interval, 1.8 to 4.9 percent) (Table 4Table 4
Risks of Second Cancers According to the Type of Treatment for Hodgkin's Disease.).The risk of leukemia rose with an increase in the alkylating-agent score (relative risk of leukemia per unit increase in the score, 1.5; 95 percent confidence interval, 1.2 to 1.8). Among the 340 patients who received a combination of mechlorethamine, vincristine, procarbazine, and prednisone, the cumulative probability of leukemia 15 years after the diagnosis of Hodgkin's disease was 2.9 percent (95 percent confidence interval, 0.7 to 5.1 percent), as compared with 0.9 percent (95 percent confidence interval, 0 to 9.5 percent) among the 103 patients who received a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine. Univariate analysis revealed that patients were at increased risk for leukemia if they had had one or more recurrences of Hodgkin's disease (relative risk, 2.3; 95 percent confidence interval, 1.2 to 5.2), a later stage (III or IV) at diagnosis (relative risk, 4.2; 1.7 to 10.3), or an older age (10 to 16) at the diagnosis of Hodgkin's disease (relative risk, 3.6; 1.1 to 12.2). The risk of leukemia was not significantly increased in the subjects who had undergone splenectomy (relative risk, 1.4; 95 percent confidence interval, 0.6 to 3.4). Of the 572 patients who underwent splenectomy, 13 had leukemia, as compared with 9 of the 637 patients who did not undergo splenectomy.
Multivariate analysis revealed that a late stage of Hodgkin's disease at diagnosis and recurrent disease independently predicted the risk of secondary leukemia. However, patients presenting with late-stage disease had a significantly higher mean (±SE) alkylating-agent score than those presenting with early-stage disease (2.4±0.06 vs. 1.2±0.04, P<0.001). Similarly, patients with recurrent Hodgkin's disease had received significantly higher cumulative doses of alkylating agents than patients with no recurrence (mean score, 2.5±0.08 vs. 1.2±0.03; P<0.001). In addition, patients who presented with late-stage disease and had also had a recurrence had significantly higher alkylating-agent scores than patients who presented with early-stage disease and had no subsequent recurrence (mean score, 3.4±0.1 vs. 0.9±0.04; P<0.001).
Of the 26 patients with leukemia, 25 died; the median survival was 2.5 months after the diagnosis of leukemia. Twenty-three patients died of secondary leukemia, one in an accident, and one of progressive Hodgkin's disease.
Lymphomas
Non-Hodgkin's lymphoma developed in six patients. The alkylating-agent score was the only significant independent risk factor for non-Hodgkin's lymphoma (relative risk, 1.7; 95 percent confidence interval, 1.2 to 2.6). Five patients with non-Hodgkin's lymphoma died; the median survival was 2.5 months. Four died of the non-Hodgkin's lymphoma, and one of progressive Hodgkin's disease.
Solid Cancers
Solid cancers developed in 56 patients. Breast cancer was the most common solid tumor, occurring in 17 patients. Ten patients had thyroid cancer, nine had basal-cell carcinomas, four had bone tumors, four had brain tumors, and three had colorectal carcinomas. Gastric carcinomas, tumors of the female genitourinary tract, parotid-gland tumors, soft-tissue sarcomas, and neuroblastoma occurred in one or two patients each. Risk factors were analyzed both with and without the inclusion of basal-cell carcinomas. There was no difference between the results of the two analyses, and so those of the latter are reported.
Sixty-six percent of the solid cancers developed in the group of patients who had received both radiation and chemotherapy (Table 4). The estimated cumulative probability of a solid tumor 20 years after the diagnosis of Hodgkin's disease was significantly higher among women (12.6 percent; 95 percent confidence interval, 6.8 to 18.4 percent) than men (3.9 percent; 1.5 to 6.3 percent). When the 17 women with breast cancer were excluded, the cumulative probability of solid tumors among the women in the group (8.8 percent; 95 percent confidence interval, 3.4 to 14.2 percent) approached that among the men (3.9 percent; 1.5 to 6.3 percent). Multivariate analysis revealed that female sex was associated with an increased risk of solid tumors (relative risk, 2.9; 95 percent confidence interval, 1.5 to 5.4). Older patients (those 10 to 16 years of age at the diagnosis of Hodgkin's disease) also appeared to be at increased risk for solid tumors (relative risk as compared with those <10 years at diagnosis, 1.8; 95 percent confidence interval, 0.96 to 4.0). Exclusion of the nine patients with basal-cell carcinoma made this association nonsignificant (relative risk, 1.6; 95 percent confidence interval, 0.8 to 3.1).
Seventeen of the 56 patients with solid tumors died. The median survival was 12.5 months after the diagnosis of the second neoplasm; 10 deaths were due to the second neoplasm and 7 to accidents.
Breast Cancer
Of the 17 women in whom breast cancer developed, 7 had received radiation therapy alone and 10 had received radiation and chemotherapy. Of the 17 cancers, 16 appeared within or at the margin of the radiation field. In one patient, the tumor (a multifocal infiltrating ductal carcinoma) occurred outside the radiation field (the patient had received radiation to the neck). Five patients had bilateral breast tumors. The majority of the tumors were infiltrating ductal or lobular carcinomas. The median age at the time of diagnosis of breast cancer was 31.5 years (range, 16 to 42). Three patients died of their breast cancer (median survival, 3 years), eight were alive with disease at this writing (median length of follow-up after diagnosis, 10 months), four were alive without disease (median length of follow-up, 4.5 years), and the status of two was unknown.
The women in our cohort of survivors of Hodgkin's disease had a risk of breast cancer that was 75 times the risk in the general population (Table 2). The risk of breast cancer was elevated throughout the follow-up period, and the interval from the diagnosis of Hodgkin's disease to the diagnosis of breast cancer was less than five years in two cases (Table 3). Figure 2Figure 2
Cumulative Probability of Breast Cancer as a Function of Age in the Cohort of Female Survivors of Hodgkin's Disease in Childhood. shows the estimated cumulative probability of breast cancer as a function of the age of the cohort of female survivors of Hodgkin's disease. The estimated actuarial cumulative probability of breast cancer was 35 percent (95 percent confidence interval, 17.4 to 52.6 percent) at 40 years of age.Univariate analysis revealed that patients who were 10 to 16 years of age when Hodgkin's disease was diagnosed and treated were at increased risk for breast cancer as compared with those who were younger than 10 at diagnosis (relative risk, 6.7; 95 percent confidence interval, 1.2 to 28.6). In addition, patients who underwent splenectomy appeared to be at increased risk for breast cancer (relative risk, 2.6; 95 percent confidence interval, 0.96 to 5.0). Patients with breast cancer received a higher dose of radiation to the mantle region (median, 4000 cGy; range, 0 to 4750) than those in whom breast cancer did not develop (median, 2000 cGy; range, 0 to 5200). Seventy-six percent of the patients who had breast cancer had received at least 2000 cGy of radiation to the mantle region, as compared with 48 percent of the patients who did not have breast cancer.
Multivariate analysis revealed that an age of more than 10 years at the time of diagnosis of Hodgkin's disease was independently associated with increased risk (relative risk, 1.9; 95 percent confidence interval, 1.1 to 3.2), as was a higher dose of radiation (as compared with a radiation dose of <2000 cGy, the relative risk for a dose between 2000 and 4000 cGy was 5.9 [1.2 to 30.3], and the relative risk for a dose exceeding 4000 cGy was 23.7 [3.7 to 152.3]).
Discussion
Among the 1380 patients who were treated for childhood Hodgkin's disease between 1955 and 1986 at 15 institutions, we found the estimated cumulative risk of a second cancer to be 7.0 percent 15 years after the initial diagnosis. This report provides evidence that the risk of a second neoplasm is increased about 18 times in long-term survivors of childhood Hodgkin's disease. The risk was highest in patients who were older when they had Hodgkin's disease, with 74 percent of the cancers occurring in those who received diagnoses between 10 and 16 years of age. This finding is similar to that reported by Beaty et al.17
Breast cancer was the most common solid tumor in this group of patients. The women in our cohort had a risk of breast cancer 75 times greater than that in the general population. Moreover, the estimated cumulative probability of breast cancer among women in our cohort who survived childhood Hodgkin's disease approached 35 percent at 40 years of age. For our multinational investigation, we used the rates of the U.S. Surveillance, Epidemiology, and End Results Program for the incidence of breast cancer in the general population19 because the age-standardized rates for France (66.2 per 100,000), Italy (65.4 per 100,000), and the United Kingdom (63.4 per 100,000) are roughly similar to that in the United States (89.2 per 100,000).22
An increased risk of breast cancer has been observed among women exposed to radiation from atomic-bomb explosions, repeated chest fluoroscopy, or treatment of postpartum mastitis.23-28 Most previous studies of large populations of patients who were treated for Hodgkin's disease did not detect a significantly elevated risk of breast cancer.17,18,29-33 This may be because of the long interval between the occurrence of Hodgkin's disease and the appearance of breast cancer. The paucity of young patients in most reported series must also be taken into account because of the association of the risk of breast cancer with younger age at the time of treatment for Hodgkin's disease.34 One study of 885 women who were treated for Hodgkin's disease with radiation before 30 years of age found a fourfold increase in the risk of breast cancer.35 However, only 76 patients in this report were less than 15 years old when Hodgkin's disease was diagnosed; 3 of those 76 patients had breast cancer.
In our study, breast cancer occurred exclusively in women. The majority of breast cancers arose within the field of radiation. We found that the risk of breast cancer increased with the dose of radiation; most breast cancers occurred in patients who had received at least 2000 cGy in the mantle region.
The increased risk of breast cancer after treatment for Hodgkin's disease was related to age at the time of radiation exposure. Sixteen of the 17 breast cancers occurred in patients who were between 10 and 16 years of age when Hodgkin's disease was diagnosed. Hancock et al. reported an increased risk of breast cancer among women who were less than 30 years old when Hodgkin's disease was diagnosed.35 In atomic-bomb survivors, an increased risk of breast cancer was found in the group of women who were in the first three decades of life when they were exposed to the radiation.27 The high incidence of breast cancer in women who are exposed to high doses of radiation between 10 and 16 years of age suggests that the tumorigenic influence of radiation mainly affects proliferating breast tissue.
We found that after a relatively short period of latency (4.4 years), the cumulative incidence of leukemia rose sharply, but it appeared to reach a plateau after 14 years, which is consistent with data from other studies.13 The dose-dependent association of alkylating agents with secondary leukemia and non-Hodgkin's lymphoma has been reported by others.15,16 The combination of doxorubicin, bleomycin, vinblastine, and dacarbazine appeared to be less leukemogenic than the combination of mechlorethamine, vincristine, procarbazine, and prednisone, but the difference was not statistically significant.
It has not been established that splenectomy is a risk factor for secondary leukemia.17,36-44 In the original cohort of 979 survivors of Hodgkin's disease in the Late Effects Study Group, splenectomy had borderline significance as a risk factor (P = 0.09),16 and in the present study, we did not find any independent relation between splenectomy and the risk of secondary leukemia or solid tumors.
In contrast to the risk of treatment-related leukemia, which plateaued after 14 years, the risk of solid tumors continued to increase beyond 15 years and approached 30 percent at 30 years. This is an important problem in survivors of Hodgkin's disease and underscores the necessity of medical monitoring. The high risk of breast cancer in women exposed to radiation at a young age raises important issues regarding screening programs (such as physical examination of the breast, sonography, mammography, and quantitative magnetic resonance imaging). We must also consider chemoprevention (tamoxifen and retinoids) for survivors of Hodgkin's disease who are at high risk for breast cancer. Efforts to develop treatments for Hodgkin's disease that are curative but less carcinogenic should continue.
Supported by the University of Minnesota Children's Cancer Research Fund and a Public Health Service Training Grant (T32 CA09607) from the National Cancer Institute.
Source Information
From the Department of Pediatrics, University of Minnesota, Minneapolis (S.B., L.L.R.); the Institut Gustave-Roussy, Villejuif, France (O.O.); the Hospital for Sick Children, Toronto (M.G.); the Children's Hospital of Philadelphia, Philadelphia (G.B., A.T.M.); and the National Tumor Institute, Milan, Italy (F.F.-B.).
Address reprint requests to Dr. Robison at the Division of Pediatric Epidemiology and Clinical Research, University of Minnesota, Box 422 UMHC, Minneapolis, MN 55455.
Appendix
In addition to the authors, the Late Effects Study Group included the following: Dana–Farber Cancer Institute, Boston — S. Sallen and F. Li; Columbus Children's Hospital, Columbus, Ohio — R. Ruymann and W. Newton; Children's Memorial Hospital, Chicago — E. Morgan; Royal Manchester Children's Hospital, Manchester, England — P. Morris-Jones and J. Birch; Emma Kinderziekenhuis, Amsterdam — P.A. Voute; Children's Hospital, Los Angeles — S. Siegel; Children's Hospital Medical Center, Cincinnati — C. DeLaat; Children's National Medical Center, Washington, D.C. — H.S. Nicholson; and Children's Hospital, Pittsburgh — J. Blatt.
- References
References
1
Devita VT Jr ,Serpick AA ,Carbone PP . Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970;73:881-895
Web of Science | Medline2
Horning SJ ,Hoppe RT ,Kaplan HS ,Rosenberg SA . Female reproductive potential after treatment for Hodgkin's disease. N Engl J Med 1981;304:1377-1382
Full Text | Web of Science | Medline3
Sherins RJ ,DeVita VT Jr . Effect of drug treatment for lymphoma on male reproductive capacity: studies of men in remission after therapy. Ann Intern Med 1973;79:216-220
Web of Science | Medline4
Rosenberg SA ,Kaplan HS . The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962-1984. Int J Radiat Oncol Biol Phys 1985;11:5-22
CrossRef | Web of Science | Medline5
Arseneau JC ,Sponzo RW ,Levin DL , et al. Nonlymphomatous malignant tumors complicating Hodgkin's disease: possible association with intensive therapy. N Engl J Med 1972;287:1119-1122
Full Text | Web of Science | Medline6
Canellos GP ,Arseneau JC ,DeVita VT ,Whang-Peng J ,Johnson RE . Second malignancies complicating Hodgkin's disease in remission. Lancet 1975;1:947-949
CrossRef | Web of Science | Medline7
Coleman CN ,Kaplan HS ,Cox R ,Varghese A ,Butterfield P ,Rosenberg SA . Leukaemias, non-Hodgkin's lymphomas and solid tumours in patients treated for Hodgkin's disease. Cancer Surv 1982;1:733-7448
Coltman CA Jr ,Dixon DO . Second malignancies complicating Hodgkin's disease: a Southwest Oncology Group 10-year follow-up. Cancer Treat Rep 1982;66:1023-1033
Medline9
Glicksman AS ,Pajak TF ,Gottlieb JA ,Nissen N ,Stutzman L ,Cooper MR . Second malignant neoplasms in patients successfully treated for Hodgkin's disease: a Cancer and Leukemia Group B study. Cancer Treat Rep 1982;66:1035-1044
Medline10
Boivin JF ,Hutchison GB ,Lyden M ,Godbold J ,Chorosh J ,Schottenfeld D . Second primary cancers following treatment of Hodgkin's disease. J Natl Cancer Inst 1984;72:233-241
Web of Science | Medline11
Koletsky AJ ,Bertino JR ,Farber LR , et al. Second neoplasms in patients with Hodgkin's disease following combined modality therapy -- the Yale experience. J Clin Oncol 1986;4:311-317
Web of Science | Medline12
Valagussa P ,Santoro A ,Fossati-Bellani F ,Banfi A ,Bonadonna G . Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 1986;4:830-837
Web of Science | Medline13
Blayney DW ,Longo DL ,Young RC , et al. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N Engl J Med 1987;316:710-714
Full Text | Web of Science | Medline14
Pederson-Bjergaard J ,Specht L ,Larsen SO , et al. Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease: relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet 1987;2:83-88
CrossRef | Web of Science | Medline15
Tucker MA ,Meadows AT ,Boice JD Jr , et al. Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst 1987;78:459-464
Web of Science | Medline16
Meadows AT ,Obringer AC ,Marrero O , et al. Second malignant neoplasms following childhood Hodgkin's disease: treatment and splenectomy as risk factors. Med Pediatr Oncol 1989;17:477-484
CrossRef | Medline17
Beaty O III ,Hudson MM ,Greenwald C , et al. Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. J Clin Oncol 1995;13:603-609
Web of Science | Medline18
Boivin JF ,Hutchison GB ,Zauber AG , et al. Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst 1995;87:732-741
CrossRef | Web of Science | Medline19
Miller BA, Ries LAG, Hankey BF, et al. SEER cancer statistics review: 1973-1990. Bethesda, Md.: National Cancer Institute, 1993. (NIH publication no. 93-2789.)
20
Vandenbroucke JP . A shortcut method for calculating the 95 per cent confidence interval of the standardized mortality ratio. Am J Epidemiol 1982;115:303-304
Web of Science21
Kaplan EL ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science22
Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell J, eds. Cancer incidence in five continents. Vol. 6. Lyon, France: International Agency for Research on Cancer, 1992. (IARC scientific publications no. 120.)
23
Mackenzie I . Breast cancer following multiple fluoroscopies. Br J Cancer 1965;19:1-8
CrossRef | Web of Science | Medline24
Miller AB ,Howe GR ,Sherman GJ , et al. Mortality from breast cancer after irradiation during fluoroscopic examinations in patients being treated for tuberculosis. N Engl J Med 1989;321:1285-1289
Full Text | Web of Science | Medline25
Shore RE ,Hildreth N ,Woodard E ,Dvoretsky P ,Hempelmann L ,Pasternack B . Breast cancer among women given X-ray therapy for acute postpartum mastitis. J Natl Cancer Inst 1986;77:689-696
Web of Science | Medline26
Baral E ,Larsson LE ,Mattson B . Breast cancer following irradiation of the breast. Cancer 1977;40:2905-2910
CrossRef | Web of Science | Medline27
Tokunaga M ,Land CE ,Yamamoto T , et al. Incidence of female breast cancer among atomic bomb survivors: Hiroshima and Nagasaki, 1950-1980. Radiat Res 1987;112:243-272
CrossRef | Web of Science | Medline28
Boice JD Jr ,Land CE ,Shore RE ,Norman JE ,Tokunaga M . Risk of breast cancer following low-dose radiation exposure. Radiology 1979;131:589-597
Web of Science | Medline29
Cimino G ,Papa G ,Tura PS , et al. Second primary cancer following Hodgkin's disease: updated results of an Italian multicentric study. J Clin Oncol 1991;9:432-437
Web of Science | Medline30
Tucker MA ,Coleman CN ,Cox RS ,Varghese A ,Rosenberg SA . Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 1988;318:76-81
Full Text | Web of Science | Medline31
Greene MH, Wilson J. Second cancer following lymphatic and hematopoietic cancers in Connecticut, 1935-82. In: Boice JD Jr, Storm HH, Curtis RE, et al., eds. Multiple primary cancers in Connecticut and Denmark. National Cancer Institute monograph 68. Washington, D.C.: Government Printing Office, 1985:191-7. (NIH publication no. 85-2714.)
32
Storm HH, Prener A. Second cancer after lymphatic and hematopoietic cancers in Denmark, 1943-80. In: Boice JD Jr, Storm HH, Curtis RE, et al., eds. Multiple primary cancers in Connecticut and Denmark. National Cancer Institute monograph 68. Washington, D.C.: Government Printing Office, 1985:389-409. (NIH publication no. 85-2714.)
33
Kaldor JM ,Day NE ,Band P , et al. Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries. Int J Cancer 1987;39:571-585
CrossRef | Web of Science | Medline34
Curtis RE ,Boice JD Jr . Second cancers after radiotherapy for Hodgkin's disease. N Engl J Med 1988;319:244-245
Full Text | Web of Science | Medline35
Hancock SL ,Tucker MA ,Hoppe RT . Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 1993;85:25-31
CrossRef | Web of Science | Medline36
van Leeuwen FE ,Somers R ,Hart AAM . Splenectomy in Hodgkin's disease and second leukaemias. Lancet 1987;2:210-211
CrossRef | Web of Science | Medline37
van der Velden JW ,van Putten WLJ ,Guinee VF , et al. Subsequent development of acute non-lymphocytic leukemia in patients treated for Hodgkin's disease. Int J Cancer 1988;42:252-255
CrossRef | Web of Science | Medline38
van Leeuwen FE ,Somers R ,Taal BG , et al. Increased risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's disease. J Clin Oncol 1989;7:1046-1058
Web of Science | Medline39
Kaldor JM ,Day NE ,Clarke EA , et al. Leukemia following Hodgkin's disease. N Engl J Med 1990;322:7-13
Full Text | Web of Science | Medline40
Tura S ,Fiacchini M ,Zinzani PL ,Brusamolino E ,Gobbi PG . Splenectomy and the increasing risk of second acute leukemia in Hodgkin's disease. J Clin Oncol 1993;11:925-930
Web of Science | Medline41
van Leeuwen FE ,Klokman WJ ,Hagenbeek A , et al. Second cancer risk following Hodgkin's disease: a 20 year follow-up study. J Clin Oncol 1994;12:312-325
Web of Science | Medline42
Andrieu J-M ,Ifrah N ,Payen C ,Fermanian J ,Coscas Y ,Flandrin G . Increased risk of second acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. J Clin Oncol 1990;8:1148-1154
Web of Science | Medline43
Abrahamsen JF ,Andersen A ,Hannisdal E , et al. Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age. J Clin Oncol 1993;11:255-261
Web of Science | Medline44
Rodriguez MA ,Fuller LM ,Zimmerman SO , et al. Hodgkin's disease: study of treatment intensities and incidences of second malignancies. Ann Oncol 1993;4:125-131
Web of Science | Medline
- Citing Articles (246)
Citing Articles
1
Aziza Shad, Scott N. Myers, Karen Hennessy. (2012) Late Effects in Cancer Survivors: “The Shared Care Model”. Current Oncology Reports
CrossRef2
Daniel B. Kopans. (2011) JUST THE FACTS: MAMMOGRAPHY SAVES LIVES WITH LITTLE IF ANY RADIATION RISK TO THE MATURE BREAST. Health Physics 101:5, 578-582
CrossRef3
V. Brillaud, C. Tunon de Lara, P. Richaud, C. Breton-Callu, V. Brouste, E. Bussières. (2011) Maladie de Hodgkin et cancer du sein : une association pour quelles patientes ? À propos d’une série de l’institut Bergonié. Gynécologie Obstétrique & Fertilité
CrossRef4
Steven C. Katz, Keith Baldwin, Giorgos Karakousis, Nicole Moraco, Anthony Buglino, Samuel Singer, Murray F. Brennan. (2011) Soft tissue sarcoma diagnosed subsequent to lymphoma is associated with prior radiotherapy and decreased survival. Cancer 117:20, 4756-4763
CrossRef5
Mattia Intra, Denise Mattar, Claudia Sangalli, Nicole Rotmensz, Giuseppe Viale, Viviana Galimberti, Alberto Luini, Paolo Veronesi, Marco Colleoni, Stefano Zurrida, Roberto Orecchia, Umberto Veronesi. (2011) Local therapy for breast cancer in malignant lymphoma survivors. The Breast 20, S99-S103
CrossRef6
Ellen A Wiegner, Sarah S Donaldson. (2011) Controversies in radiotherapy for pediatric Hodgkin’s lymphoma. Expert Review of Anticancer Therapy 11:9, 1357-1366
CrossRef7
Sergio Cortelazzo, Maurilio Ponzoni, Andrés J.M. Ferreri, Dieter Hoelzer. (2011) Lymphoblastic lymphoma. Critical Reviews in Oncology/Hematology 79:3, 330-343
CrossRef8
Gregory M. Cote, George P. Canellos. (2011) Can Low-Risk, Early-Stage Patients with Hodgkin Lymphoma Be Spared Radiotherapy?. Current Hematologic Malignancy Reports 6:3, 180-186
CrossRef9
Ali Varan, Rejin Kebudi. (2011) Secondary Malignant Neoplasms After Childhood Cancer. Pediatric Hematology-Oncology 28:5, 345-353
CrossRef10
K. Doi, M. N. Mieno, Y. Shimada, H. Yonehara, S. Yoshinaga. (2011) Meta-analysis of second cancer risk after radiotherapy among childhood cancer survivors. Radiation Protection Dosimetry 146:1-3, 263-267
CrossRef11
K. Nottage, J. Lanctot, Z. Li, J. P. Neglia, S. Bhatia, S. Hammond, W. Leisenring, A. Meadows, D. Srivastava, L. L. Robison, G. T. Armstrong. (2011) Long-term risk for subsequent leukemia after treatment for childhood cancer: a report from the Childhood Cancer Survivor Study. Blood 117:23, 6315-6318
CrossRef12
Lynda M. Vrooman, Donna S. Neuberg, Kristen E. Stevenson, Barbara L. Asselin, Uma H. Athale, Luis Clavell, Peter D. Cole, Kara M. Kelly, Eric C. Larsen, Caroline Laverdière, Bruno Michon, Marshall Schorin, Cindy L. Schwartz, Harvey J. Cohen, Steven E. Lipshultz, Lewis B. Silverman, Stephen E. Sallan. (2011) The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium. European Journal of Cancer 47:9, 1373-1379
CrossRef13
Markhaba Tukenova, Catherine Guibout, Mike Hawkins, Eric Quiniou, Abddedahir Mousannif, Hélène Pacquement, David Winter, André Bridier, Dimitri Lefkopoulos, Odile Oberlin, Ibrahima Diallo, Florent de Vathaire. (2011) Radiation Therapy and Late Mortality From Second Sarcoma, Carcinoma, and Hematological Malignancies After a Solid Cancer in Childhood. International Journal of Radiation Oncology*Biology*Physics 80:2, 339-346
CrossRef14
C. Furth, H. Amthauer, H. Hautzel, I. G. Steffen, J. Ruf, J. Schiefer, S. Schonberger, G. Henze, R. Grandt, P. Hundsdoerfer, M. Dietlein, C. Kobe. (2011) Evaluation of interim PET response criteria in paediatric Hodgkin's lymphoma--results for dedicated assessment criteria in a blinded dual-centre read. Annals of Oncology 22:5, 1198-1203
CrossRef15
Amaury Paumier, Mithra Ghalibafian, Anne Beaudre, Ivaldo Ferreira, Charlotte Pichenot, Taha Messai, Nathalie Athalie Lessard, Dimitri Lefkopoulos, Theodore Girinsky. (2011) Involved-Node Radiotherapy and Modern Radiation Treatment Techniques in Patients With Hodgkin Lymphoma. International Journal of Radiation Oncology*Biology*Physics 80:1, 199-205
CrossRef16
Sophie Haberer, Lisa Belin, Romuald Le Scodan, Youlia M. Kirova, Alexia Savignoni, Denise Stevens, Patricia Moisson, Didier Decaudin, Jean-Yves Pierga, Fabien Reyal, François Campana, Alain Fourquet, Marc A. Bollet. (2011) Locoregional Treatment for Breast Carcinoma After Hodgkin’s Lymphoma: The Breast Conservation Option. International Journal of Radiation Oncology*Biology*Physics
CrossRef17
K. M. Kelly, R. Sposto, R. Hutchinson, V. Massey, K. McCarten, S. Perkins, M. Lones, D. Villaluna, M. Weiner. (2011) BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. Blood 117:9, 2596-2603
CrossRef18
M. Scholz, A. Engert, J. Franklin, A. Josting, V. Diehl, D. Hasenclever, M. Loeffler. (2011) Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis. Annals of Oncology 22:3, 681-688
CrossRef19
A Yokota, S Ozawa, T Masanori, H Akiyama, K Ohshima, Y Kanda, S Takahashi, T Mori, C Nakaseko, M Onoda, K Kishi, N Doki, N Aotsuka, H Kanamori, A Maruta, H Sakamaki, S Okamoto. (2011) Secondary solid tumors after allogeneic hematopoietic SCT in Japan. Bone Marrow Transplantation
CrossRef20
Bruno Cutuli, Samia Kanoun, Christine Tunon De Lara, Marc Baron, Lorenzo Livi, Cristelle Levy, Christine Cohen-Solal-Lenir, Anne Lesur, Pierre Kerbrat, Mariano Provencio, Laurence Gonzague-Casabianca, Alice Mege, Claire Lemanski, Catherine Delva, Sylvie Lancrenon, Michel Velten. (2011) Breast cancer occurred after Hodgkin's disease: Clinico-pathological features, treatments and outcome: Analysis of 214 cases. Critical Reviews in Oncology/Hematology
CrossRef21
Matthew Koshy, Shayna E. Rich, Usama Mahmood, Young Kwok. (2011) Declining Use of Radiotherapy in Stage I and II Hodgkin’s Disease and Its Effect on Survival and Secondary Malignancies. International Journal of Radiation OncologyBiologyPhysics
CrossRef22
Janet S de Moor, Elaine Puleo, Jennifer S Ford, Mark Greenberg, David C Hodgson, Vida L Tyc, Jamie Ostroff, Lisa R Diller, Andrea Levy, Kim Sprunck-Harrild, Karen M Emmons. (2011) Disseminating a smoking cessation intervention to childhood and young adult cancer survivors: baseline characteristics and study design of the partnership for health-2 study. BMC Cancer 11:1, 165
CrossRef23
Takushi Miyoshi, Shinji Takebayashi, Chiaki Suzuki, Nao Hiwatashi, Hiroki Ikeda, Kazuo Ono, Makoto Miura. (2011) Early-Onset Postirradiation Sarcoma of the Tongue after Pseudotumor Phase. ORL 73:4, 201-205
CrossRef24
María Sol Brassesco, Danilo Jordão Xavier, Marjori Leiva Camparoto, Ana Paula Montaldi, Paulo Roberto D'Auria Vieira de Godoy, Carlos Alberto Scrideli, Luiz Gonzaga Tone, Elza Tiemi Sakamoto-Hojo. (2011) Cytogenetic Instability in Childhood Acute Lymphoblastic Leukemia Survivors. Journal of Biomedicine and Biotechnology 2011, 1-9
CrossRef25
Sonia K. A. Nguyen, Anne Dagnault. (2010) Breast-conserving therapy after previous irradiation for lymphoma. Breast Cancer Research and Treatment 124:3, 845-849
CrossRef26
Gregory T. Armstrong, Marilyn Stovall, Leslie L. Robison. (2010) Long-Term Effects of Radiation Exposure among Adult Survivors of Childhood Cancer: Results from the Childhood Cancer Survivor Study. Radiation Research 174:6b, 840-850
CrossRef27
Mian Xi, Meng-Zhong Liu, Hai-Xia Wang, Ling Cai, Li Zhang, Chun-Fang Xie, Qiao-Qiao Li. (2010) Radiation-induced sarcoma in patients with nasopharyngeal carcinoma. Cancer 116:23, 5479-5486
CrossRef28
Jennifer L. Griffin, Mark D. Pearlman. (2010) Breast Cancer Screening in Women at Average Risk and High Risk. Obstetrics & Gynecology 116:6, 1410-1421
CrossRef29
Jeremy Franklin, Dennis Eichenauer, Ina Monsef, Andreas Engert, Jeremy Franklin. 2010. Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival. .
CrossRef30
Geoffrey P. Schembri, Anne E. Miller, Richard Smart. (2010) Radiation Dosimetry and Safety Issues in the Investigation of Pulmonary Embolism. Seminars in Nuclear Medicine 40:6, 442-454
CrossRef31
Jonathan Sive, David Linch. 2010. Hodgkin Lymphoma. , 639-654.
CrossRef32
Jarrod B. Adkison, Robert R. Kuske, Rakesh R. Patel. (2010) Breast Conserving Surgery and Accelerated Partial Breast Irradiation After Prior Breast Radiation Therapy. American Journal of Clinical Oncology 33:5, 427-431
CrossRef33
Wendy S. Rubinstein. (2010) Endocrine Cancer Predisposition Syndromes: Hereditary Paraganglioma, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, and Hereditary Thyroid Cancer. Hematology/Oncology Clinics of North America 24:5, 907-937
CrossRef34
Wolfgang Dörffel, Dieter Körholz. 2010. Hodgkin's Lymphoma. , 130-148.
CrossRef35
Rawad Rihani, Faiha Bazzeh, Nesreen Faqih, Iyad Sultan. (2010) Secondary hematopoietic malignancies in survivors of childhood cancer. Cancer 116:18, 4385-4394
CrossRef36
Daniel B. Kopans. (2010) The 2009 US Preventive Services Task Force (USPSTF) Guidelines are not Supported by Science: The Scientific Support for Mammography Screening. Radiologic Clinics of North America 48:5, 843-857
CrossRef37
Edward A. Sickles. (2010) The Use of Breast Imaging to Screen Women at High Risk for Cancer. Radiologic Clinics of North America 48:5, 859-878
CrossRef38
Norman E. Breslow, Jane M. Lange, Debra L. Friedman, Daniel M. Green, Mike M. Hawkins, Michael F.G. Murphy, Joseph P. Neglia, Jørgen H. Olsen, Susan M. Peterson, Charles A. Stiller, Leslie L. Robison. (2010) Secondary malignant neoplasms after Wilms tumor: An international collaborative study. International Journal of Cancer 127:3, 657-666
CrossRef39
D. L. Friedman, J. Whitton, W. Leisenring, A. C. Mertens, S. Hammond, M. Stovall, S. S. Donaldson, A. T. Meadows, L. L. Robison, J. P. Neglia. (2010) Subsequent Neoplasms in 5-Year Survivors of Childhood Cancer: The Childhood Cancer Survivor Study. JNCI Journal of the National Cancer Institute 102:14, 1083-1095
CrossRef40
Icro Meattini, Lorenzo Livi, Calogero Saieva, Livia Marrazzo, Andrea Rampini, Carmine Iermano, Maria Grazia Papi, Beatrice Detti, Silvia Scoccianti, Giampaolo Biti. (2010) Breast Cancer Following Hodgkin’s Disease: The Experience of the University of Florence. The Breast Journal 16:3, 290-296
CrossRef41
Youssef Al-Tonbary, Mohamed M. Sarhan, Rasha A. El-Ashry, Emad Salama, Mohamed Sedky, Ashraf Fouda. (2010) Comparative study of two mechlorethamine, vincristine, procarbazine, and prednisone derived chemotherapeutic protocols for the management of pediatric Hodgkin lymphoma (HL): single-center 5-year experience. Leukemia & Lymphoma 51:4, 656-663
CrossRef42
, Paula Manchon, Josep M. Borràs, Tàrsila Ferro, Josep Alfons Espinàs. (2010) Breast cancer OncoGuia. Clinical and Translational Oncology 12:2, 113-137
CrossRef43
Young-Ho Lee. (2010) Late physical effects of childhood cancer survivors. Korean Journal of Pediatrics 53:4, 477
CrossRef44
Carol H. Lee, D. David Dershaw, Daniel Kopans, Phil Evans, Barbara Monsees, Debra Monticciolo, R. James Brenner, Lawrence Bassett, Wendie Berg, Stephen Feig, Edward Hendrick, Ellen Mendelson, Carl D'Orsi, Edward Sickles, Linda Warren Burhenne. (2010) Breast Cancer Screening With Imaging: Recommendations From the Society of Breast Imaging and the ACR on the Use of Mammography, Breast MRI, Breast Ultrasound, and Other Technologies for the Detection of Clinically Occult Breast Cancer. Journal of the American College of Radiology 7:1, 18-27
CrossRef45
James H. Garvin Jr. 2010. Gender-Specific Aspects of Pediatric Hematology and Oncology. , 51-61.
CrossRef46
Pierre-Yves Marcy, Juliette Thariat, Anne Sudaka, Gilles Poissonnet. (2009) Synchronous Parathyroid and Papillary Thyroid Carcinomas. Thyroid 19:10, 1131-1133
CrossRef47
C. L. Schwartz, L. S. Constine, D. Villaluna, W. B. London, R. E. Hutchison, R. Sposto, S. E. Lipshultz, C. S. Turner, P. A. deAlarcon, A. Chauvenet. (2009) A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood 114:10, 2051-2059
CrossRef48
Sughosh Dhakal, Tithi Biswas, Jane L. Liesveld, Jonathan W. Friedberg, Gordon L. Phillips, Louis S. Constine. (2009) Patterns and Timing of Initial Relapse in Patients Subsequently Undergoing Transplantation for Hodgkin's Lymphoma. International Journal of Radiation Oncology*Biology*Physics 75:1, 188-192
CrossRef49
S J Howell, C Searle, V Goode, T Gardener, K Linton, R A Cowan, M A Harris, P Hopwood, R Swindell, A Norman, J Kennedy, A Howell, A M Wardley, J A Radford. (2009) The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage. British Journal of Cancer 101:4, 582-588
CrossRef50
Ajay Niranjan, Douglas Kondziolka, L. Dade Lunsford. (2009) Neoplastic Transformation After Radiosurgery or Radiotherapy: Risk and Realities. Otolaryngologic Clinics of North America 42:4, 717-729
CrossRef51
Frank G. Keller, Sharon M. Castellino, James B. Nachman. (2009) What is the best treatment for children with limited-stage Hodgkin lymphoma?. Current Hematologic Malignancy Reports 4:3, 129-135
CrossRef52
Smita Bhatia, Louis S. Constine. (2009) Late Morbidity After Successful Treatment of Children with Cancer. The Cancer Journal 15:3, 174-180
CrossRef53
Maurice Tubiana. (2009) Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review. Radiotherapy and Oncology 91:1, 4-15
CrossRef54
Manjeet Chadha, Harold Yoon, Sheldon Feldman, Niral Shah, Eric Moore, Louis B. Harrison. (2009) Partial Breast Brachytherapy as the Primary Treatment for Breast Cancer Diagnosed After Mantle Radiation Therapy for Hodgkinʼs Disease. American Journal of Clinical Oncology 32:2, 132-136
CrossRef55
Sue C. Kaste. (2009) Imaging challenges: a US perspective on controlling exposure to ionizing radiation in children with cancer. Pediatric Radiology 39:S1, 74-79
CrossRef56
Martha S. Linet, Kwang pyo Kim, Preetha Rajaraman. (2009) Children’s exposure to diagnostic medical radiation and cancer risk: epidemiologic and dosimetric considerations. Pediatric Radiology 39:S1, 4-26
CrossRef57
Larry E. Kun, Chris Beltran. (2009) Radiation therapy for children: evolving technologies in the era of ALARA. Pediatric Radiology 39:S1, 65-70
CrossRef58
Mohamed A. Alm El-Din, Kevin S. Hughes, Dianne M. Finkelstein, Keith A. Betts, Torunn I. Yock, Nancy J. Tarbell, Alan C. Aisenberg, Alphonse G. Taghian. (2009) Breast Cancer After Treatment of Hodgkin's Lymphoma: Risk Factors That Really Matter. International Journal of Radiation Oncology*Biology*Physics 73:1, 69-74
CrossRef59
Sherri Sheinfeld Gorin, Patrick McAuliffe. (2009) Implications of childhood cancer survivors in the classroom and the school. Health Education 109:1, 25-48
CrossRef60
Nobuko Hijiya, Kirsten K. Ness, Raul C. Ribeiro, Melissa M. Hudson. (2009) Acute leukemia as a secondary malignancy in children and adolescents: Current findings and issues. Cancer 115:1, 23-35
CrossRef61
Mohamed A. Alm El-Din, Samy A. El-Badawy, Alphonse G. Taghian. (2008) Breast Cancer After Treatment of Hodgkin's Lymphoma: General Review. International Journal of Radiation Oncology*Biology*Physics 72:5, 1291-1297
CrossRef62
Raoul C. Reulen, Aliki J. Taylor, David L. Winter, Charles A. Stiller, Clare Frobisher, Emma R. Lancashire, Fabienne M. McClanahan, Elaine M. Sugden, Mike M. Hawkins, . (2008) Long-term population-based risks of breast cancer after childhood cancer. International Journal of Cancer 123:9, 2156-2163
CrossRef63
Hae-June Lee, Yoon-Jin Lee, Chang-Mo Kang, Sangwoo Bae, Dooil Jeoung, Ja-June Jang, Seung-Sook Lee, Chul-Koo Cho, Yun-Sil Lee. (2008) Differential Gene Signatures in Rat Mammary Tumors Induced by DMBA and Those Induced by Fractionated γ Radiation. Radiation Research 170:5, 579-590
CrossRef64
Louis S. Constine, Nancy Tarbell, Melissa M. Hudson, Cindy Schwartz, Susan G. Fisher, Ann G. Muhs, Swati K. Basu, Larry E. Kun, Andrea Ng, Peter Mauch, Ajay Sandhu, Eva Culakova, Gary Lyman, Nancy Mendenhall. (2008) Subsequent Malignancies in Children Treated for Hodgkin's Disease: Associations With Gender and Radiation Dose. International Journal of Radiation Oncology*Biology*Physics 72:1, 24-33
CrossRef65
Swati K. Basu, Cindy Schwartz, Susan G. Fisher, Melissa M. Hudson, Nancy Tarbell, Ann Muhs, Karen J. Marcus, Nancy Mendenhall, Peter Mauch, Larry E. Kun, Louis S. Constine. (2008) Unilateral and Bilateral Breast Cancer in Women Surviving Pediatric Hodgkin's Disease. International Journal of Radiation Oncology*Biology*Physics 72:1, 34-40
CrossRef66
J. Ritter. (2008) Hodgkin-Lymphome bei Kindern und Jugendlichen. best practice onkologie 3:4, 18-32
CrossRef67
B. Ashleigh Guadagnolo, Gunar K. Zagars, Matthew T. Ballo, Sara S. Strom, Raphael E. Pollock, Robert S. Benjamin. (2008) Mortality after cure of soft‐tissue sarcoma treated with conservation surgery and radiotherapy. Cancer 113:2, 411-418
CrossRef68
X George Xu, Bryan Bednarz, Harald Paganetti. (2008) A review of dosimetry studies on external-beam radiation treatment with respect to second cancer induction. Physics in Medicine and Biology 53:13, R193-R241
CrossRef69
Irina Dinu, Yan Liu, Wendy Leisenring, Ann C. Mertens, Joseph P. Neglia, Sue Hammond, Leslie L. Robison, Yutaka Yasui. (2008) Prediction of second malignant neoplasm incidence in a large cohort of long-term survivors of childhood cancers. Pediatric Blood & Cancer 50:5, 1026-1031
CrossRef70
Daniel A. Mulrooney, Douglas C. Dover, Suwen Li, Yutaka Yasui, Kirsten K. Ness, Ann C. Mertens, Joseph P. Neglia, Charles A. Sklar, Leslie L. Robison, Stella M. Davies, . (2008) Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia. Cancer 112:9, 2071-2079
CrossRef71
Gill Levitt, Debra Eshelman. 2008. Long-Term Effects of Cancer Treatment. , 167-191.
CrossRef72
Yavuz Koksal, Hatice Toy, Ekrem Unal, Tamer Baysal, Hasan Esen, Yahya Paksoy, M. Erkan Ustun. (2008) Pilocytic astrocytoma developing at the site of a previously treated medulloblastoma in a child. Child's Nervous System 24:3, 289-292
CrossRef73
Sandra Brennan, Lucy E. Hann, Joachim Yahalom, Kevin C. Oeffinger, Jürgen Rademaker. (2008) Imaging of Late Complications from Mantle Field Radiation in Lymphoma Patients. Radiologic Clinics of North America 46:2, 419-430
CrossRef74
Michael R. Olson, Sarah S. Donaldson. (2008) Treatment of Pediatric Hodgkin Lymphoma. Current Treatment Options in Oncology 9:1, 81-94
CrossRef75
Uri Tabori, Giselle Revach, Paul C. Nathan, Brigitte Strahm, Alisa Rachlis, Mary Shago, Ronald Grant, John Doyle, David Malkin. (2008) Toxicity and outcome of children with treatment related acute myeloid leukemia. Pediatric Blood & Cancer 50:1, 17-23
CrossRef76
Thomas Lowe, Thehang Luu, Jeannie Shen, George Somlo. (2008) Male Breast Cancer 15 Years after Allogeneic Hematopoietic Cell Transplantation Including Total Body Irradiation for Recurrent Acute Lymphoblastic Leukemia. Onkologie 31:5, 266-269
CrossRef77
Ava Kwong, Steven L. Hancock, Joan R. Bloom, Sunita Pal, Robyn L. Birdwell, Carol Mariscal, Debra M. Ikeda. (2008) Mammographic Screening in Women at Increased Risk of Breast Cancer after Treatment of Hodgkin’s Disease. The Breast Journal 14:1, 39-48
CrossRef78
Kate Absolom, Diana Greenfield, Richard Ross, Helena Davies, Barry Hancock, Christine Eiser. (2007) Reassurance following breast screening recall for female survivors of Hodgkin's lymphoma. The Breast 16:6, 590-596
CrossRef79
Peter D. Inskip, Rochelle E. Curtis. (2007) New malignancies following childhood cancer in the United States, 1973–2002. International Journal of Cancer 121:10, 2233-2240
CrossRef80
Ronald D. Barr. (2007) Common cancers in adolescents. Cancer Treatment Reviews 33:7, 597-602
CrossRef81
Theodore Girinsky, Mithra Ghalibafian, Guillaume Bonniaud, Aziz Bayla, Nicolas Magne, Ivaldo Ferreira, Jean Lumbroso. (2007) Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting?. Radiotherapy and Oncology 85:2, 178-186
CrossRef82
Thomas Lowe, Smita Bhatia, George Somlo. (2007) Second Malignancies after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation 13:10, 1121-1134
CrossRef83
G. W. Hall, N. Katzilakis, C. R. Pinkerton, G. Nicolin, S. Ashley, Keith McCarthy, S. Daw, M. Hewitt, W. H. Wallace, A. Shankar. (2007) Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children's Cancer and Leukaemia Group report. British Journal of Haematology 138:6, 761-768
CrossRef84
Esther M. John, Amanda I. Phipps, Julia A. Knight, Roger L. Milne, Gillian S. Dite, John L. Hopper, Irene L. Andrulis, Melissa Southey, Graham G. Giles, Dee W. West, Alice S. Whittemore. (2007) Medical radiation exposure and breast cancer risk: Findings from the Breast Cancer Family Registry. International Journal of Cancer 121:2, 386-394
CrossRef85
Michael Jacob Adams, Louis S. Constine, Steven E. Lipshultz. (2007) Late effects of therapy for Hodgkin’s lymphoma. Current Hematologic Malignancy Reports 2:3, 143-150
CrossRef86
Stella M. Davies. (2007) Subsequent malignant neoplasms in survivors of childhood cancer: Childhood Cancer Survivor Study (CCSS) studies. Pediatric Blood & Cancer 48:7, 727-730
CrossRef87
S. Stoneham, S. Ashley, Ross Pinkerton, Martin Hewitt, W.H.B. Wallace, A.G. Shankar. (2007) Hodgkin’s lymphoma in children aged 5 years or less – The United Kingdom experience. European Journal of Cancer 43:9, 1415-1421
CrossRef88
M. Waheed Roomi, Vadim Ivanov, Tatiana Kalinovsky, Aleksandra Niedzwiecki, Matthias Rath. (2007) Inhibition of glioma cell line A-172 MMP activity and cell invasion in vitro by a nutrient mixture. Medical Oncology 24:2, 231-238
CrossRef89
Michael Capra, Martin Hewitt, Martin Radford, Janis Hayward, Claire L. Weston, David Machin. (2007) Long-term outcome in children with Hodgkin’s lymphoma: The United Kingdom Children’s Cancer Study Group HD82 trial. European Journal of Cancer 43:7, 1171-1179
CrossRef90
Janet S. Moor, Elaine Puleo, Rita M. Butterfield, Frederick P. Li, Karen M. Emmons. (2007) Availability of smoking prevention and cessation services for childhood cancer survivors. Cancer Causes & Control 18:4, 423-430
CrossRef91
Line Claude, Claude Malet, Pascal Pommier, Philippe Thiesse, Sylvie Chabaud, Christian Carrie. (2007) Active Breathing Control for Hodgkin’s Disease in Childhood and Adolescence: Feasibility, Advantages, and Limits. International Journal of Radiation Oncology*Biology*Physics 67:5, 1470-1475
CrossRef92
Martin Hutchings, Annika Loft, Mads Hansen, Anne Kiil Berthelsen, Lena Specht. (2007) Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. European Journal of Haematology 78:3, 206-212
CrossRef93
Sharon L. Bober, Elyse R. Park, Terra Schmookler, Cheryl Medeiros Nancarrow, Lisa Diller. (2007) Perceptions of breast cancer risk and cancer screening: A qualitative study of Young, female Hodgkin’s Disease survivors. Journal of Cancer Education 22:1, 42-46
CrossRef94
Mark D. Miller, Melanie A. Marty, Rachel Broadwin, Kenneth C. Johnson, Andrew G. Salmon, Bruce Winder, Craig Steinmaus. (2007) The association between exposure to environmental tobacco smoke and breast cancer: A review by the California Environmental Protection Agency. Preventive Medicine 44:2, 93-106
CrossRef95
Irena Buka, Samuel Koranteng, Alvaro R. Osornio Vargas. (2007) Trends in Childhood Cancer Incidence: Review of Environmental Linkages. Pediatric Clinics of North America 54:1, 177-203
CrossRef96
Patrick Mansky, Andrew Arai, Pamela Stratton, Donna Bernstein, Lauren Long, James Reynolds, Donna Chen, Seth M. Steinberg, Neil Lavende, Karen Hoffman, Paul C. Nathan, Rebecca Parks, Elizabeth Augustine, Usha Chaudhry, Joanne Derdak, Lori Wiener, Lynn Gerber, Crystal Mackall. (2007) Treatment late effects in long-term survivors of pediatric sarcoma. Pediatric Blood & Cancer 48:2, 192-199
CrossRef97
Sylvie Guérin, Catherine Guibout, Akthar Shamsaldin, Marie-Gabrielle Dondon, Ibrahima Diallo, Mike Hawkins, Odile Oberlin, Olivier Hartmann, Jean Michon, Marie-Cécile Le Deley, Florent de Vathaire. (2007) Concomitant chemo-radiotherapy and local dose of radiation as risk factors for second malignant neoplasms after solid cancer in childhood: A case–control study. International Journal of Cancer 120:1, 96-102
CrossRef98
Michael Weintraub, Eitan Gross, Avishag Kadari, Vardit Ravitsky, Anat Safran, Neri Laufer, Ariel Revel. (2007) Should ovarian cryopreservation be offered to girls with cancer. Pediatric Blood & Cancer 48:1, 4-9
CrossRef99
Jonathan Tward, Martha Glenn, Michael Pulsipher, Phillip Barnette, David Gaffney. (2007) Incidence, risk factors, and pathogenesis of second malignancies in patients with non-Hodgkin lymphoma. Leukemia & Lymphoma 48:8, 1482-1495
CrossRef100
Edita Kabickova, David Sumerauer, Eliska Cumlivska, Eva Drahokoupilova, Michaela Nekolna, Marketa Chanova, Marie Hladikova, Roman Kodet, Otakar Belohlavek. (2006) Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin’s disease. European Journal of Nuclear Medicine and Molecular Imaging 33:9, 1025-1031
CrossRef101
Jennifer S. Ford, Jamie S. Ostroff. (2006) Health Behaviors of Childhood Cancer Survivors: What We’ve Learned. Journal of Clinical Psychology in Medical Settings 13:2, 144-160
CrossRef102
Carolyn S. Rabin, Bernardine M. Pinto, Joseph J. Trunzo, Georita M. Frierson, Lynn M. Bucknam. (2006) Physical activity among breast cancer survivors: regular exercisers vs participants in a physical activity intervention. Psycho-Oncology 15:4, 344-354
CrossRef103
Ronald D. Barr, Mark L. Greenberg. (2006) Cancer surveillance and control in adolescents—similarities and contrasts between Canada and the United States. Pediatric Blood & Cancer 46:3, 273-277
CrossRef104
D M Greenfield, J Wright, J E Brown, B W Hancock, H A Davies, L O'toole, C Eiser, R E Coleman, R J Ross. (2006) High incidence of late effects found in Hodgkin's lymphoma survivors, following recall for breast cancer screening. British Journal of Cancer 94:4, 469-472
CrossRef105
T.J. FitzGerald, Jesse Aronowitz, M. Giulia Cicchetti, Graeme Fisher, Sidney Kadish, Y.C. Lo, Charles Mayo, Shelagh McCauley, Joshua Meyer, Richard Pieters, Alexandra Sherman. (2006) The Effect of Radiation Therapy on Normal Tissue Function. Hematology/Oncology Clinics of North America 20:1, 141-163
CrossRef106
Smita Bhatia, Anna T. Meadows. (2006) Long-term follow-up of childhood cancer survivors: Future directions for clinical care and research. Pediatric Blood & Cancer 46:2, 143-148
CrossRef107
Rafael Martinez-Monge, Mauricio Cambeiro, Mikel San-Julián, Luis Sierrasesúmaga. (2006) Use of brachytherapy in children with cancer: the search for an uncomplicated cure. The Lancet Oncology 7:2, 157-166
CrossRef108
Tatsuhiko Imaoka, Mieko Okamoto, Mayumi Nishimura, Yukiko Nishimura, Masami Ootawara, Shizuko Kakinuma, Yutaka Tokairin, Yoshiya Shimada. (2006) Mammary Tumorigenesis in Apc Min/+ Mice is Enhanced by X Irradiation with a Characteristic Age Dependence. Radiation Research 165:2, 165-173
CrossRef109
Martine van Grotel, King H. Lam, Rogier de Man, Auke Beishuizen, Rob Pieters, Marry M. van den Heuvel-EiBrink. (2006) High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only. Leukemia & Lymphoma 47:8, 1504-1510
CrossRef110
Laxman S. Arya, Veronique Dinand, Vasantha Thavaraj, Sameer Bakhshi, Ramesh Dawar, Goura K. Rath, Rajvir Singh, Tribhuvan S. Vats. (2006) Hodgkin's disease in Indian children: Outcome with chemotherapy alone. Pediatric Blood & Cancer 46:1, 26-34
CrossRef111
Robert E Goldsby, Denah R Taggart, Arthur R Ablin. (2006) Surviving Childhood Cancer. Pediatric Drugs 8:2, 71-84
CrossRef112
Melissa M. Hudson. (2005) A model for care across the cancer continuum. Cancer 104:S11, 2638-2642
CrossRef113
Jeremy Franklin, Marcus D Paus, Annette Pluetschow, Lena Specht, Jeremy Franklin. 2005. Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk. .
CrossRef114
Philip M. Rosoff, Nicole Larrier, Henry E. Rice. (2005) Intra-abdominal desmoid tumor after successful treatment for Hodgkin disease. Pediatric Blood & Cancer 45:5, 728-731
CrossRef115
Catherine Bauld, J.W. Toumbourou, V. Anderson, C. Coffey, C.A. Olsson. (2005) Health-risk behaviours among adolescent survivors of childhood cancer. Pediatric Blood & Cancer 45:5, 706-715
CrossRef116
L. B. Travis, D. Hill, G. M. Dores, M. Gospodarowicz, F. E. van Leeuwen, E. Holowaty, B. Glimelius, M. Andersson, E. Pukkala, C. F. Lynch, D. Pee, S. A. Smith, M. B. Van't Veer, T. Joensuu, H. Storm, M. Stovall, J. D. Boice, E. Gilbert, M. H. Gail. (2005) Cumulative Absolute Breast Cancer Risk for Young Women Treated for Hodgkin Lymphoma. JNCI Journal of the National Cancer Institute 97:19, 1428-1437
CrossRef117
Richard C. Chao, Urszula Pyzel, Jane Fridlyand, Yien-Ming Kuo, Lewis Teel, Jennifer Haaga, Alexander Borowsky, Andrew Horvai, Scott C. Kogan, Jeannette Bonifas, Bing Huey, Tyler E. Jacks, Donna G. Albertson, Kevin M. Shannon. (2005) Therapy-induced malignant neoplasms in Nf1 mutant mice. Cancer Cell 8:4, 337-348
CrossRef118
Mahmoud Aljurf, Syed Z.A. Zaidi. (2005) Chemotherapy and Hematopoietic Stem Cell Transplantation for Adult T-Cell Lymphoblastic Lymphoma: Current Status and Controversies. Biology of Blood and Marrow Transplantation 11:10, 739-754
CrossRef119
G. Ralleigh. (2005) Screening for breast cancer in women with previous mantle radiotherapy for Hodgkin's disease. Breast Cancer Online 8:10,
CrossRef120
Bidhu K. Mohanti, Manishi Bansal. (2005) Late sequelae of radiotherapy in adults. Supportive Care in Cancer 13:10, 775-780
CrossRef121
Paul Lorigan, John Radford, Anthony Howell, Nick Thatcher. (2005) Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. The Lancet Oncology 6:10, 773-779
CrossRef122
John Milner, Elizabeth Jeffery. 2005. Diet and Cancer Prevention. .
CrossRef123
K. Behringer, A. Engert. (2005) Spätschäden nach Behandlung des Hodgkin-Lymphoms. Der Onkologe 11:9, 959-967
CrossRef124
Donna M. Hammal, Claire L. Bell, Alan W. Craft, Louise Parker. (2005) Second primary tumors in children and young adults in the North of England (1968-99). Pediatric Blood & Cancer 45:2, 155-161
CrossRef125
Cindy L. Schwartz. (2005) Special issues in pediatric Hodgkin's disease. European Journal of Haematology 75, 55-62
CrossRef126
Ralph M. Meyer. (2005) Is there convincing evidence for the use of chemotherapy alone in patients with limited stage Hodgkin's lymphoma?. European Journal of Haematology 75, 115-120
CrossRef127
Smita Bhatia, Wendy Landier. (2005) Evaluating Survivors of Pediatric Cancer. The Cancer Journal 11:4, 340-354
CrossRef128
Emma-Louise Dormand, Paul E Banwell, Timothy EE Goodacre. (2005) Radiotherapy and wound healing. International Wound Journal 2:2, 112-127
CrossRef129
Tatsuhiko Imaoka, Mayumi Nishimura, Ayako Teramoto, Yukiko Nishimura, Masami Ootawara, Harumi Osada, Shizuko Kakinuma, Akihiko Maekawa, Yoshiya Shimada. (2005) Cooperative induction of rat mammary cancer by radiation and 1-methyl-1-nitrosourea via the oncogenic pathways involving c-Myc activation and H-ras mutation. International Journal of Cancer 115:2, 187-193
CrossRef130
Christophe Locher, Yoram Bouhnik, Judith Nemeth, Yves Panis, Mourad Boudiaf, Anne Lavergne-Slove, Claude Matuchansky. (2005) Tumeur endocrine du pancréas après pancréatite chronique radique. Gastroentérologie Clinique et Biologique 29:3, 306-308
CrossRef131
Xiang-qian Su, Chun-yi Hao, Fei Gao. (2005) Metachronous second primary cancers: Clinical analyses of 506 cases in a single institution. Chinese Journal of Cancer Research 17:1, 57-62
CrossRef132
Kirsten K. Ness, J. Michael Oakes, Judith A. Punyko, K. Scott Baker, James G. Gurney. (2005) Prevalence of the Metabolic Syndrome in Relation to Self-reported Cancer History. Annals of Epidemiology 15:3, 202-206
CrossRef133
P.J. Hoskin, P. Smith, T.S. Maughan, D. Gilson, C. Vernon, I. Syndikus, D.C. Linch. (2005) Long-term results of a randomised trial of involved field radiotherapy vs extended field radiotherapy in stage I and II Hodgkin lymphoma. Clinical Oncology 17:1, 47-53
CrossRef134
Han-Ming Joseph Lin, Michael A Teitell. (2005) Second Malignancy After Treatment of Pediatric Hodgkin Disease. Journal of Pediatric Hematology/Oncology 27:1, 28-36
CrossRef135
Alexandru Daşu, Iuliana Toma-Daşu, Jörgen Olofsson, Mikael Karlsson. (2005) The use of risk estimation models for the induction of secondary cancers following radiotherapy. Acta Oncologica 44:4, 339-347
CrossRef136
Ann C. Mertens, Pauline A. Mitby, Gretchen Radloff, Irene M. Jones, John Perentesis, William R. Kiffmeyer, Joseph P. Neglia, Anna Meadows, John D. Potter, Debra Friedman, Yutaka Yasui, Leslie L. Robison, Stella M. Davies. (2004) XRCC1 and glutathione-S-transferase gene polymorphisms and susceptibility to radiotherapy-related malignancies in survivors of Hodgkin disease. Cancer 101:6, 1463-1472
CrossRef137
Merideth M. M. Wendland, Alexander Tsodikov, Martha J. Glenn, David K. Gaffney. (2004) Time interval to the development of breast carcinoma after treatment for Hodgkin disease. Cancer 101:6, 1275-1282
CrossRef138
Friederike G.A.J. Hakvoort-Cammel, Saskia Buitendijk, Marry van den Heuvel-Eibrink, Karel H
hlen. (2004) Treatment of pediatric Hodgkin disease avoiding radiotherapy: Excellent outcome with the Rotterdam-HD-84-protocol. Pediatric Blood & Cancer 43:1, 8-16
CrossRef139
Janez Jazbec, Patricija E?imovi?, Berta Jereb. (2004) Second neoplasms after treatment of childhood cancer in Slovenia. Pediatric Blood & Cancer 42:7, 574-581
CrossRef140
Theresa B Haddy, Revonda B Mosher, Patricia A Dinndorf, Gregory H Reaman. (2004) Second neoplasms in survivors of childhood and adolescent cancer are often treatable. Journal of Adolescent Health 34:4, 324-329
CrossRef141
H. van den Berg, F. Furstner, C. van den Bos, H. Behrendt. (2004) Decreasing the number of MOPP courses reduces gonadal damage in survivors of childhood hodgkin disease. Pediatric Blood & Cancer 42:3, 210-215
CrossRef142
Gregory M. Chronowski, Richard B. Wilder, Larry B. Levy, Edward N. Atkinson, Chul S. Ha, Fredrick B. Hagemeister, Ibrahim Barista, Maria A. Rodriguez, Andreas H. Sarris, Mark A. Hess, Fernando Cabanillas, James D. Cox. (2004) Second Malignancies After Chemotherapy and Radiotherapy for Hodgkin Disease. American Journal of Clinical Oncology 27:1, 73-80
CrossRef143
Ruth Warren, Michelle Harvie, Anthony Howell. (2004) Strategies for Managing Breast Cancer Risk After the Menopause. Treatments in Endocrinology 3:5, 289-307
CrossRef144
L Yung, P Smith, BW Hancock, P Hoskin, D Gilson, C Vernon, DC Linch. (2004) Long Term Outcome in Adolescents with Hodgkin's Lymphoma: Poor Results using Regimens Designed for Adults. Leukemia & Lymphoma 45:8, 1579-1585
CrossRef145
Charles E. Land, Masayoshi Tokunaga, Kojiro Koyama, Midori Soda, Dale L. Preston, Issei Nishimori, Shoji Tokuoka. (2003) Incidence of Female Breast Cancer among Atomic Bomb Survivors, Hiroshima and Nagasaki, 1950–1990. Radiation Research 160:6, 707-717
CrossRef146
Vikas Kundra, Paul M Silverman. (2003) Impact of multislice CT on imaging of acute abdominal disease. Radiologic Clinics of North America 41:6, 1083-1093
CrossRef147
Teri Vega-Stromberg. (2003) Chemotherapy-induced Secondary Malignancies. Journal of Infusion Nursing 26:6, 353-361
CrossRef148
Bruno Fuchs, Richard G. Valenzuela, Ivy A. Petersen, Carola A. Arndt, Franklin H. Sim. (2003) Ewing???s Sarcoma and the Development of Secondary Malignancies. Clinical Orthopaedics and Related Research 415, 82-89
CrossRef149
Leslie L. Robison, Smita Bhatia. (2003) Late-effects among survivors of leukaemia and lymphoma during childhood and adolescence. British Journal of Haematology 122:3, 345-359
CrossRef150
F. E. van Leeuwen, W. J. Klokman, M. Stovall, E. C. Dahler, M. B. van't Veer, E. M. Noordijk, M. A. Crommelin, B. M. P. Aleman, A. Broeks, M. Gospodarowicz, L. B. Travis, N. S. Russell. (2003) Roles of Radiation Dose, Chemotherapy, and Hormonal Factors in Breast Cancer Following Hodgkin's Disease. JNCI Journal of the National Cancer Institute 95:13, 971-980
CrossRef151
Leslie L Robison. (2003) Research involving long-term survivors of childhood and adolescent cancer: methodologic considerations. Current Problems in Cancer 27:4, 212-224
CrossRef152
Brian Weiss, Amish Vora, John Huberty, Randall A. Hawkins, Katherine K. Matthay. (2003) Secondary Myelodysplastic Syndrome and Leukemia Following 131I-Metaiodobenzylguanidine Therapy for Relapsed Neuroblastoma. Journal of Pediatric Hematology/Oncology 25:7, 543-547
CrossRef153
Elaine Ron. (2003) CANCER RISKS FROM MEDICAL RADIATION. Health Physics 85:1, 47-59
CrossRef154
Daniel B. Kopans, Elizabeth Rafferty, Diane Georgian-Smith, Eren Yeh, Helen D'Alessandro, Richard Moore, Kevin Hughes, Elkan Halpern. (2003) A simple model of breast carcinoma growth may provide explanations for observations of apparently complex phenomena. Cancer 97:12, 2951-2959
CrossRef155
A. Carmichael, A.S. Sami, J.M. Dixon. (2003) Breast cancer risk among the survivors of atomic bomb and patients exposed to therapeutic ionising radiation. European Journal of Surgical Oncology (EJSO) 29:5, 475-479
CrossRef156
Jay S. Loeffler, Andrzej Niemierko, Paul H. Chapman. (2003) Second Tumors after Radiosurgery: Tip of the Iceberg or a Bump in the Road?. Neurosurgery 52:6, 1436-1442
CrossRef157
D. L. Wahner-Roedler, D. F. Nelson, I. T. Croghan, S. J. Achenbach, C. S. Crowson, L. C. Hartmann, W. M. O'Fallon. (2003) Risk of Breast Cancer and Breast Cancer Characteristics in Women Treated With Supradiaphragmatic Radiation for Hodgkin Lymphoma: Mayo Clinic Experience. Mayo Clinic Proceedings 78:6, 708-715
CrossRef158
Douglas G. Gold, Joseph P. Neglia, Kathryn E. Dusenbery. (2003) Second neoplasms after megavoltage radiation for pediatric tumors. Cancer 97:10, 2588-2596
CrossRef159
Daniel M. Green. (2003) Late effects of treatment for cancer during childhood and adolescence. Current Problems in Cancer 27:3, 127-142
CrossRef160
Anna T. Meadows. (2003) Pediatric cancer survivors: past history and future challenges. Current Problems in Cancer 27:3, 112-126
CrossRef161
Kevin C. Oeffinger. (2003) Longitudinal risk-based health care for adult survivors of childhood cancer. Current Problems in Cancer 27:3, 143-167
CrossRef162
G Klein, J Michaelis, C Spix, R Wibbing, G Eggers, J Ritter, P Kaatsch. (2003) Second malignant neoplasms after treatment of childhood cancer. European Journal of Cancer 39:6, 808-817
CrossRef163
Kenan Deniz, Susan O'Mahony, Gillian Ross, Anand Purushotham. (2003) Breast cancer in women after treatment for Hodgkin's disease. The Lancet Oncology 4:4, 207-214
CrossRef164
Cindy L. Schwartz. (2003) The management of Hodgkin disease in the young child. Current Opinion in Pediatrics 15:1, 10-16
CrossRef165
LeLe Aung, Richard G. Gorlick, Weiji Shi, Howard Thaler, Nicholas A. Shorter, John H. Healey, Andrew G. Huvos, Paul A. Meyers. (2002) Second malignant neoplasms in long-term survivors of osteosarcoma. Cancer 95:8, 1728-1734
CrossRef166
Joachim Yahalom. (2002) Changing role and decreasing size: Current trends in radiotherapy for hodgkin’s disease. Current Oncology Reports 4:5, 415-423
CrossRef167
Pierre R Band, Nhu D Le, Raymond Fang, Michèle Deschamps. (2002) Carcinogenic and endocrine disrupting effects of cigarette smoke and risk of breast cancer. The Lancet 360:9339, 1044-1049
CrossRef168
Patricia A Ganz. (2002) The price of anticancer intervention. The Lancet Oncology 3:9, 575-579
CrossRef169
WILLIAM H. HINDLE, NAIRY SARKIS. (2002) Breast Cancer and Masses in Women 22 Years of Age and Younger. Clinical Obstetrics and Gynecology 45:3, 758-760
CrossRef170
Vincent Delwail, Jean-Philippe Jais, Pierre Colonna, Jean-Marie Andrieu. (2002) Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation. British Journal of Haematology 118:1, 189-194
CrossRef171
Melissa M. Hudson, V.L. Tyc, D.K. Srivastava, J. Gattuso, A. Quargnenti, D.B. Crom, P. Hinds. (2002) Multi-component behavioral intervention to promote health protective behaviors in childhood cancer survivors: The Protect Study. Medical and Pediatric Oncology 39:1, 2-11
CrossRef172
Fernando C. Maluf, Lisa M. DeAngelis, Jeffrey J. Raizer, Lauren E. Abrey. (2002) High-grade gliomas in patients with prior systemic malignancies. Cancer 94:12, 3219-3224
CrossRef173
J.R. Kowalczyk, J. Nurzy?ska, J. Armata, J. Bogus?awska-Jaworska, R. Rokicka-Milewska, D. So?ta-Jakimczyk, W. Balwierz, A. Chybicka, M. Kaczmarek-Kanold, P. Ko?ecki, M. Matysiak, K. Pawelec. (2002) Second malignant neoplasms in children: A multicenter study of the Polish Pediatric Leukemia/Lymphoma Group. Medical and Pediatric Oncology 38:6, 421-423
CrossRef174
Bouthaina S. Dabaja, Chul S. Ha, Deborah A. Thomas, Richard B. Wilder, Ramesh Gopal, Jorge Cortes, Carlos Bueso-Ramos, Mark A. Hess, James D. Cox, Hagop M. Kantarjian. (2002) The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma. Cancer 94:10, 2738-2744
CrossRef175
M. Deutsch, M.R. Wollman, R. Ramanathan, J. Rubin. (2002) Rectal cancer twenty-one years after treatment of childhood Hodgkin disease. Medical and Pediatric Oncology 38:4, 280-281
CrossRef176
T E Robsahm, S Tretli. (2002) Breast cancer incidence in food- vs non-food-producing areas in Norway: possible beneficial effects of World War II. British Journal of Cancer 86:3, 362-366
CrossRef177
Smita Bhatia, Charles Sklar. (2002) SECOND CANCERS IN SURVIVORS OF CHILDHOOD CANCER. Nature Reviews Cancer 2:2, 124-132
CrossRef178
Norma Bacilious, Peter G. Cordeiro, Joseph J. Disa, David A. Hidalgo. (2002) Breast Reconstruction Using Tissue Expanders and Implants in Hodgkin???s Patients with Prior Mantle Irradiation. Plastic and Reconstructive Surgery 109:1, 102-107
CrossRef179
Kazuo Muroi, Chizuru Kawano, Taiji Yokote, Tetsuya Otsuki, Keita Kirito, Norio Komatsu, Keiya Ozawa. (2002) Early Myelodysplastic Syndrome After Allogeneic Bone Marrow Transplantation for Acute Myeloid Leukemia. Leukemia & Lymphoma 43:7, 1493-1496
CrossRef180
Ursula Rühl, Marion Albrecht, Karin Dieckmann, Heike Lüders, Heinz Marciniak, Dörte Schellenberg, Lutz Wickmann, Wolfgang Dörffel. (2001) Response-adapted radiotherapy in the treatment of pediatric Hodgkin’s disease: an interim report at 5 years of the German GPOH-HD 95 trial. International Journal of Radiation Oncology*Biology*Physics 51:5, 1209-1218
CrossRef181
Cvetka Bilban-Jakopin, Marjan Bilban. (2001) Genotoxic effects of radiotherapy and chemotherapy on circulating lymphocytes in patients with Hodgkin’s disease. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 497:1-2, 81-88
CrossRef182
Georgina W. Hall. (2001) Childhood myeloid leukaemias. Best Practice & Research Clinical Haematology 14:3, 573-591
CrossRef183
Melissa A. McDiarmid, Patricia W. Gucer. (2001) The ???GRAS??? Status of Women???s Work. Journal of Occupational and Environmental Medicine 43:8, 665-669
CrossRef184
Amy Y. Chen, Lawrence Levy, Helmuth Goepfert, Barry W. Brown, Margaret R. Spitz, Rena Vassilopoulou-Sellin. (2001) The development of breast carcinoma in women with thyroid carcinoma. Cancer 92:2, 225-231
CrossRef185
John Moppett, Anthony Oakhill, Andrew W. Duncan. (2001) Second malignancies in children: the usual suspects?. European Journal of Radiology 38:3, 235-248
CrossRef186
Kathryn M. Kash, Mary Kay Dabney. (2001) Psychological aspects of cancer screening in high-risk populations. Medical and Pediatric Oncology 36:5, 519-524
CrossRef187
Stephen A. Feig. (2001) Second Malignant Neoplasms after Successful Treatment of Childhood Cancers. Blood Cells, Molecules, and Diseases 27:3, 662-666
CrossRef188
John D. Boice. (2001) Radiation and breast carcinogenesis. Medical and Pediatric Oncology 36:5, 508-513
CrossRef189
J. P. Neglia, D. L. Friedman, Y. Yasui, A. C. Mertens, S. Hammond, M. Stovall, S. S. Donaldson, A. T. Meadows, L. L. Robison. (2001) Second Malignant Neoplasms in Five-Year Survivors of Childhood Cancer: Childhood Cancer Survivor Study. JNCI Journal of the National Cancer Institute 93:8, 618-629
CrossRef190
Virginia M. Hamilton, Cynthia Norris, Nancy Bunin, Joel W. Goldwein, Greta R. Bunin, Beverly Lange, Anna T. Meadows. (2001) Cyclophosphamide-Based, Seven-Drug Hybrid and Low-Dose Involved Field Radiation for the Treatment of Childhood and Adolescent Hodgkin Disease. Journal of Pediatric Hematology/Oncology 23:2, 84-88
CrossRef191
John Moppett, Anthony Oakhill, Andrew W. Duncan. (2001) Second malignancies in children: the usual suspects?. European Journal of Radiology 37:2, 95-108
CrossRef192
Deborah A. Thomas, Hagop M. Kantarjian. (2001) Lymphoblastic Lymphoma. Hematology/Oncology Clinics of North America 15:1, 51-95
CrossRef193
Abbe J. Janov, Mark Tulecke, Anne O'neill, Susan Lester, Peter M. Mauch, Jay Harris, Stuart J. Schnitt, Charles L. Shapiro. (2001) Clinical and Pathologic Features of Breast Cancers in Women Treated for Hodgkin's Disease: A Case-Control Study. The Breast Journal 7:1, 46-52
CrossRef194
E. Várady, B. Deák, Zs. Molnár, A. Rosta, T. Schneider, O. Ésik, S. Eckhardt. (2001) Second Malignancies after Treatment for Hodgkin's Disease. Leukemia & Lymphoma 42:6, 1275-1281
CrossRef195
Stanislaw Garwicz, Harald Anderson, J
CrossRef196
H Boussen, L Kochbati, M Besbes, T Dhiab, R Makhlouf, G Jerbi, A Gamoudi, F Benna, K Rahal, M Maalej. (2000) Cancer du sein secondaire chez l’homme après traitement pour maladie de Hodgkin. À propos d’un cas et revue de la littérature. Cancer/Radiothérapie 4:6, 465-468
CrossRef197
H.H. Lucraft. (2000) Strategies to Reduce Deaths from Breast Cancer Following Mantle Irradiation. Clinical Oncology 12:5, 276-277
CrossRef198
Amanda L. Kim, Conrad V. Fernandez, Wenda L. Greer, David Hogg, Norman J. Lassam, Lothar Resch. (2000) Concurrent Acute Lymphoblastic Leukemia and Juvenile Pilocytic Astrocytoma in a Pediatric Patient. Journal of Pediatric Hematology/Oncology 22:5, 451-453
CrossRef199
M. Clemons, L. Loijens, P. Goss. (2000) Breast cancer risk following irradiation for Hodgkin’s disease. Cancer Treatment Reviews 26:4, 291-302
CrossRef200
Michele Morin Doody, John E. Lonstein, Marilyn Stovall, David G. Hacker, Nickolas Luckyanov, Charles E. Land. (2000) Breast Cancer Mortality After Diagnostic Radiography. Spine 25:16, 2052-2063
CrossRef201
Adnan Aydiner, Ahmet Karadeniz, Kazim Uygun, Siirsel Tas, Faruk Tas, Rian Disci, Erkan Topuz. (2000) Multiple Primary Neoplasms at a Single Institution. American Journal of Clinical Oncology: Cancer Clinical Trials 23:4, 364-370
CrossRef202
Stella M. Davies. (2000) THERAPY-RELATED LEUKEMIA. Journal of Pediatric Hematology/Oncology 22:4, 302-305
CrossRef203
Houchingue Eghbali, Pierre Soubeyran, Nadine Tchen, Isabelle de Mascarel, Isabelle Soubeyran, Pierre Richaud. (2000) Current treatment of Hodgkin’s disease. Critical Reviews in Oncology/Hematology 35:1, 49-73
CrossRef204
(2000) Assessing the Risk of Breast Cancer. New England Journal of Medicine 342:26, 2002-2003
Full Text205
K. R. HORWOOD, H. SAMARATUNGA. (2000) Primary vaginal non-Hodgkin's lymphoma after radiotherapy for Hodgkin's disease. Australian and New Zealand Journal of Medicine 30:3, 404-405
CrossRef206
R. W. Bartstra, P. A J. Bentvelzen, J. Zoetelief, A. H. Mulder, J. J. Broerse, D. W. van Bekkum. (2000) The Effects of Fractionated Gamma Irradiation on Induction of Mammary Carcinoma in Normal and Estrogen-Treated Rats. Radiation Research 153:5, 557-569
CrossRef207
Alexander Powers, Charles Cox, Douglas S. Reintgen. (2000) Breast cancer screening in childhood cancer survivors. Medical and Pediatric Oncology 34:3, 210-212
CrossRef208
Melvin Deutsch, Samuel A. Jacobs. (2000) Kaposi Sarcoma After Treatment of Hodgkin’s Disease in a Young Adult Non-AIDS Patient. American Journal of Clinical Oncology: Cancer Clinical Trials 23:1, 26-28
CrossRef209
Wallace Akerley. (2000) Secondary leukemia. Cancer 88:3, 497-499
CrossRef210
Smita Bhatia, Lilian Estrada-Batres, Tamara Maryon, Monica Bogue, David Chu. (1999) Second primary tumors in patients with cutaneous malignant melanoma. Cancer 86:10, 2014-2020
CrossRef211
Kathy Ruble, Katherine Patterson Kelly. (1999) Radiation therapy in childhood cancer. Seminars in Oncology Nursing 15:4, 292-302
CrossRef212
A. Wirth, M. Wolf, H. M. Prince. (1999) Current trends in the management of early stage Hodgkin's disease. Australian and New Zealand Journal of Medicine 29:4, 535-544
CrossRef213
Melvin Deutsch, Maury Rosenstein, Judith H. Figura. (1999) Meningioma After Radiotherapy for Hodgkin's Disease. American Journal of Clinical Oncology 22:4, 361-363
CrossRef214
Roger M. Macklis, Richard L. Crownover, Joseph Crowe, Twyla Willoughby, Jason Sohn. (1999) Reducing Scatter Radiation to the Contralateral Breast With a Mobile, Conformal Shield During Breast Cancer Radiotherapy. American Journal of Clinical Oncology 22:4, 419-425
CrossRef215
Jean E. Mulder. (1999) Benefits and risks of hormone replacement therapy in young adult cancer survivors with gonadal failure. Medical and Pediatric Oncology 33:1, 46-52
CrossRef216
Amanda M. Rauck, Daniel M. Green, Y. Yasui, A. Mertens, L.L. Robison. (1999) Marriage in the survivors of childhood cancer: A preliminary description from the childhood cancer survivor study. Medical and Pediatric Oncology 33:1, 60-63
CrossRef217
Ronald D. Barr. (1999) On cancer control and the adolescent. Medical and Pediatric Oncology 32:6, 404-410
CrossRef218
Henry Ekert, Ian Toogood, Peter Downie, Peter J. Smith, S. Macfarlane, Les White. (1999) High incidence of treatment failure with vincristine, etoposide, epirubicin, and prednisolone chemotherapy with successful salvage in childhood Hodgkin disease. Medical and Pediatric Oncology 32:4, 255-258
CrossRef219
Jens J. Froelich, Folker R. G. Schneller, Rudolf K. Zahn. (1999) The Influence of Radiation and Chemotherapy-Related DNA Strand Breaks on Carcinogenesis: An Evaluation. Clinical Chemistry and Laboratory Medicine 37:4, 403-408
CrossRef220
J COSSET, C FERME, M HENRYAMAR, P CARDE. (1999) Le rôle de la radiothérapie dans les formes localisées de maladie de Hodgkin en 1999: limitations et perspectives. Cancer/Radiothérapie 3:2, 112-118
CrossRef221
Ronald Bukowski. (1999) Cytoprotection in the treatment of pediatric cancer: Review of current strategies in adults and their application to children. Medical and Pediatric Oncology 32:2, 124-134
CrossRef222
David E. Wazer, Vimla Band. (1999) Molecular and anatomic considerations in the pathogenesis of breast cancer. Radiation Oncology Investigations 7:1, 1-12
CrossRef223
Emile Salloum, Lynn T. Tanoue, Frans JTh. Wackers, Daniel Zelterman, Grace L. Hu, Dennis L. Cooper. (1999) Assessment of Cardiac and Pulmonary Function in Adult Patients with Hodgkin's Disease Treated with ABVD or MOPP/ABVD Plus Adjuvant Low-Dose Mediastinal Irradiation. Cancer Investigation 17:3, 171-180
CrossRef224
Sandra L Blethen. (1998) Leukemia in Children Treated with Growth Hormone. Trends in Endocrinology & Metabolism 9:9, 367-370
CrossRef225
Yves Perel, Guy Leverger, Anne Carrere, Michel Caudry, Erea Noel Garabedian, Sophie Ansoborlo, Pierre Vergnes. (1998) Second thyroid neoplasms after prophylactic cranial irradiation for acute lymphoblastic leukemia. American Journal of Hematology 59:1, 91-94
CrossRef226
Karsten Nysom, Kirsten Holm, Henrik Hertz, Birger Hesse. (1998) Risk factors for reduced pulmonary function after malignant lymphoma in childhood. Medical and Pediatric Oncology 30:4, 240-248
CrossRef227
S. C. Kaste, M. M. Hudson, D. J. Jones, R. Fryrear, C. A. Greenwald, I. D. Fleming, C. B. Pratt. (1998) Breast masses in women treated for childhood cancer. Cancer 82:4, 784-792
CrossRef228
Machiko Sawada, Masaru Kubota, Ying-Wei Lin, Ken-ichiro Watanabe, Seiji Koishi, Ikuya Usami, Yuichi Akiyama, Takafumi Matsumura, Kenshi Furusho. (1998) Evaluation of mutant frequencies at the hprt and the T-cell receptor loci in pediatric cancer patients before treatment. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 397:2, 337-343
CrossRef229
StÉPhanie Oddou, Norbert Vey, Patrice Viens, ValÉRie Jeanne Bardou, Catherine Faucher, Anne Marie Stoppa, Christian Chabannon, Jacques Camerlo, RÉDa Bouabdallah, Jean Albert Gastaut, Dominique Maraninchi, Didier Blaise. (1998) Second Neoplasms Following High-dose Chemotherapy and Autologous Stem Cell Transplantation for Malignant Lymphomas: A Report of Six Cases in a Cohort of 171 Patients from a Single Institution. Leukemia & Lymphoma 31:1-2, 187-194
CrossRef230
J HABRAND, P BONDIAU, O DUPUIS, C LEVYPIEDBOIS, J MARIN, O OBERLIN. (1997) Effets tardifs de la radioth
CrossRef231
MICHAEL B. SPORN. (1997) The War on Cancer: A Review. Annals of the New York Academy of Sciences 833:1 Cancer, 137-146
CrossRef232
Magrath, Ian, . (1997) Limiting Therapy for Limited Childhood Non-Hodgkin's Lymphoma. New England Journal of Medicine 337:18, 1304-1306
Full Text233
Detlev Latz, Michael F. Wannenmacher. (1997) Solide Malignome nach Knochenmarktransplantation. Strahlentherapie und Onkologie 173:10, 530-531
CrossRef234
B CUTULI, A DELAROCHEFORDIERE, F DHERMAIN, C BOREL, Y GRAIC, B DELAFONTAN, J DILHYUDY, H MIGNOTTE, E TESSIER, J TORTOCHAUX. (1997) Cancer du sein bilatéral après maladie de Hodgkin. Particularités clinico-histologiques et possibilités thérapeutiques: analyse de 13 cas. Cancer/Radiothérapie 1:4, 300-306
CrossRef235
M P Little, F de Vathaire, M W Charles, M M Hawkins, C R Muirhead. (1997) Variations with time and age in the relative risks of solid cancer incidence after radiation exposure. Journal of Radiological Protection 17:3, 159-177
CrossRef236
Smita Bhatia, Anna T Meadows, Leslie L Robison. (1997) Family history of patients with breast cancer after treatment of Hodgkin's disease in childhood. The Lancet 350:9081, 888-889
CrossRef237
Gwyn Bebb, Barry Glickman, Karen Gelmon, Richard Gatti. (1997) “AT risk” for breast cancer. The Lancet 349:9068, 1784-1785
CrossRef238
Curtis, Rochelle E., Rowlings, Philip A., Deeg, H. Joachim, Shriner, Donna A., Socié, Gérard, Travis, Lois B., Horowitz, Mary M., Witherspoon, Robert P., Hoover, Robert N., Sobocinski, Kathleen A., Fraumeni, Joseph F. Jr., Boice, John D. Jr., Schoch, H. Gary, Sale, George E., Storb, Rainer, Travis, William D., Kolb, Hans-Jochem, Gale, Robert Peter, Passweg, Jakob R., . (1997) Solid Cancers after Bone Marrow Transplantation. New England Journal of Medicine 336:13, 897-904
Full Text239
Alan C. Aisenberg, Dianne M. Finkelstein, Karen P. Doppke, Frederick C. Koerner, Jean-Fran
CrossRef240
Leif E. Peterson, Armin D. Weinberg, Zoann E. Dreyer, Sharon E. Plon, Janice L. Smith, Philip L. Mccarthy. (1997) Design and analysis of epidemiological studies of excess cancer among children exposed to chernobyl radionuclides. STEM CELLS 15:S1, 211-230
CrossRef241
Colin M. Furnival. (1997) BREAST CANCER: CURRENT ISSUES IN DIAGNOSIS AND TREATMENT. ANZ Journal of Surgery 67:1, 47-58
CrossRef242
Anita Gustavsson. (1997) Editorial: The Long-Term Consequences of Therapy for Hodgkin's Disease Are Still Evolving. Acta Oncologica 36:1, 1-2
CrossRef243
Andrew Renehan, E. Neville Gleave, Mark McGurk. (1996) An analysis of the treatment of 114 patients with recurrent pleomorphic adenomas of the parotid gland. The American Journal of Surgery 172:6, 710-714
CrossRef244
(1996) Late Effects of Treatment for Childhood Hodgkin's Disease. New England Journal of Medicine 335:5, 352-355
Full Text245
M.B. Sporn. (1996) The war on cancer. The Lancet 347:9012, 1377-1381
CrossRef246
Donaldson, Sarah S., Hancock, Steven L., . (1996) Second Cancers after Hodgkin's Disease in Childhood. New England Journal of Medicine 334:12, 792-794
Full Text
- Letters
